$BNGO
Bionano Genomics, Inc.

2020 Q4 Form 10-Q Financial Statement

#000141169020000022 Filed on November 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $3.990M $2.196M $2.789M
YoY Change 43.06% -33.72% -30.51%
Cost Of Revenue $2.810M $1.460M $1.691M
YoY Change 66.2% -38.53% -43.42%
Gross Profit $1.180M $736.0K $1.098M
YoY Change 7.43% -21.54% 7.11%
Gross Profit Margin 29.57% 33.52% 39.38%
Selling, General & Admin $9.030M $8.659M $5.860M
YoY Change 54.1% 94.63% 27.39%
% of Gross Profit 765.25% 1176.49% 533.52%
Research & Development $2.880M $2.304M $2.400M
YoY Change 20.0% 5.98% -4.76%
% of Gross Profit 244.07% 313.04% 218.51%
Depreciation & Amortization $570.0K $320.0K $320.0K
YoY Change 78.13% 15.03% 113.33%
% of Gross Profit 48.31% 43.48% 29.13%
Operating Expenses $11.91M $10.96M $8.260M
YoY Change 44.19% 65.53% 16.01%
Operating Profit -$10.73M -$10.23M -$7.162M
YoY Change 49.83% 79.89% 17.51%
Interest Expense -$610.0K $589.0K -$870.0K
YoY Change -29.89% 1.9% 222.22%
% of Operating Profit
Other Income/Expense, Net -$10.00K -$535.0K $550.0K
YoY Change -101.82% -24.54% -1475.0%
Pretax Income -$11.74M -$10.76M -$7.890M
YoY Change 48.8% 68.31% 23.28%
Income Tax -$10.00K $30.00K $10.00K
% Of Pretax Income
Net Earnings -$11.73M -$10.79M -$7.900M
YoY Change 48.48% 68.68% 23.22%
Net Earnings / Revenue -293.98% -491.44% -283.24%
Basic Earnings Per Share -$0.08
Diluted Earnings Per Share -$74.66K -$0.08 -$282.8K
COMMON SHARES
Basic Shares Outstanding 153.2M shares 132.9M shares 26.49M shares
Diluted Shares Outstanding 132.9M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.45M $18.90M $17.30M
YoY Change 122.25% 130.49% 4.85%
Cash & Equivalents $38.45M $18.90M $17.30M
Short-Term Investments $0.00
Other Short-Term Assets $462.0K $1.900M $457.1K
YoY Change 1.08% 173.31% 18.99%
Inventory $3.315M $4.593M $3.444M
Prepaid Expenses
Receivables $2.775M $3.860M $6.334M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $46.79M $29.24M $28.26M
YoY Change 65.58% 63.91% 22.73%
LONG-TERM ASSETS
Property, Plant & Equipment $4.910M $3.635M $1.950M
YoY Change 151.84% 165.73% 9.7%
Goodwill $7.173M $6.941M $0.00
YoY Change
Intangibles $1.475M $1.580M $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $103.0K $0.00
YoY Change
Total Long-Term Assets $13.66M $12.16M $1.950M
YoY Change 600.7% 788.64% 9.7%
TOTAL ASSETS
Total Short-Term Assets $46.79M $29.24M $28.26M
Total Long-Term Assets $13.66M $12.16M $1.950M
Total Assets $60.45M $41.40M $30.21M
YoY Change 100.11% 115.52% 21.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.930M $5.665M $2.699M
YoY Change 8.55% 115.05% 99.68%
Accrued Expenses $5.599M $4.466M $3.225M
YoY Change 73.59% 30.13% 11.22%
Deferred Revenue $416.0K $412.0K $358.0K
YoY Change 16.2% -1.41% 32.1%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $14.24M $20.08M
YoY Change -100.0%
Total Short-Term Liabilities $8.945M $24.78M $26.37M
YoY Change -66.08% 233.21% 482.97%
LONG-TERM LIABILITIES
Long-Term Debt $16.33M $1.775M $0.00
YoY Change -90.55% -100.0%
Other Long-Term Liabilities $0.00 $75.00K $44.48K
YoY Change -100.0% -49.02% -94.5%
Total Long-Term Liabilities $16.33M $1.850M $44.48K
YoY Change 36602.71% -90.22% -99.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.945M $24.78M $26.37M
Total Long-Term Liabilities $16.33M $1.850M $44.48K
Total Liabilities $25.37M $26.72M $26.59M
YoY Change -4.61% 0.5% 81.34%
SHAREHOLDERS EQUITY
Retained Earnings -$143.7M -$132.0M -$102.6M
YoY Change 40.04% 39.42% 41.01%
Common Stock $178.8M $146.6M $106.2M
YoY Change 68.34% 67.96% 28.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.08M $14.68M $3.613M
YoY Change
Total Liabilities & Shareholders Equity $60.45M $41.40M $30.21M
YoY Change 100.11% 115.52% 21.79%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income -$11.73M -$10.79M -$7.900M
YoY Change 48.48% 68.68% 23.22%
Depreciation, Depletion And Amortization $570.0K $320.0K $320.0K
YoY Change 78.13% 15.03% 113.33%
Cash From Operating Activities -$12.10M -$10.96M -$9.480M
YoY Change 27.64% 52.65% 131.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$20.00K
YoY Change -100.0% -100.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$2.450M
YoY Change
Cash From Investing Activities $0.00 -$2.450M -$20.00K
YoY Change -100.0% 24400.0% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 31.68M 15.09M 18.59M
YoY Change 70.41% 12475.0% -62066.67%
NET CHANGE
Cash From Operating Activities -12.10M -10.96M -9.480M
Cash From Investing Activities 0.000 -2.450M -20.00K
Cash From Financing Activities 31.68M 15.09M 18.59M
Net Change In Cash 19.58M 1.680M 9.090M
YoY Change 115.4% -123.76% -320.1%
FREE CASH FLOW
Cash From Operating Activities -$12.10M -$10.96M -$9.480M
Capital Expenditures $0.00 $0.00 -$20.00K
Free Cash Flow -$12.10M -$10.96M -$9.460M
YoY Change 27.91% 52.86% 131.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001411690
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38613
dei Entity Registrant Name
EntityRegistrantName
Bionano Genomics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1756290
dei Entity Address Address Line1
EntityAddressAddressLine1
9540 Towne Centre Drive, Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
888-7600
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
153186000 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18867000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17311000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3860000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6334000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
4593000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
3444000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1920000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1169000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
29240000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
28258000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3635000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1950000 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1580000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 USD
CY2020Q3 us-gaap Goodwill
Goodwill
6941000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
0 USD
CY2020Q3 us-gaap Assets
Assets
41396000 USD
CY2019Q4 us-gaap Assets
Assets
30208000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5665000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2699000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4466000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3225000 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
412000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
358000 USD
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
14239000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
20085000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24782000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26367000 USD
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1775000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
88000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
183000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
75000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
26720000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
26594000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
148348000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
148348000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34274000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34274000 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
15000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
146614000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
106188000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131953000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102577000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
14676000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3614000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41396000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30208000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2196000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3313000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4513000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7340000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1460000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2375000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2919000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5077000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2304000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2174000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7379000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6682000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8659000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4449000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21640000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14295000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
10963000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
6623000 USD
us-gaap Costs And Expenses
CostsAndExpenses
29019000 USD
us-gaap Costs And Expenses
CostsAndExpenses
20977000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10227000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5685000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-27425000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-18714000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
589000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
578000 USD
us-gaap Interest Expense
InterestExpense
1911000 USD
us-gaap Interest Expense
InterestExpense
1613000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-709000 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1333000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-131000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-241000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-535000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1911000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3187000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10762000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6394000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29336000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21901000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10792000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6398000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29376000 USD
us-gaap Profit Loss
ProfitLoss
-29376000 USD
us-gaap Net Income Loss
NetIncomeLoss
-21914000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.06
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
132942000 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10898000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86632000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10662000 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10137000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
289000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2410000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
630000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
202000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7852000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
5870000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
336000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
103000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7665000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-1345000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
364000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6398000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-7379000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3614000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10792000 USD
CY2020Q1 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2355000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10510000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4213000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16366000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21000 USD
CY2020Q2 bngo Stock Issued During Period Value Covenant Waiver
StockIssuedDuringPeriodValueCovenantWaiver
300000 USD
CY2020Q2 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1109000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8074000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5837000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
447000 USD
CY2020Q3 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
15083000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4101000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
14676000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29376000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-98000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1334000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Profit Loss
ProfitLoss
-29376000 USD
us-gaap Profit Loss
ProfitLoss
-21914000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
909000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
815000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
952000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
523000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1103000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
990000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1333000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1709000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1486000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3612000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1886000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
566000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2450000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26210000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
925000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20148000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
19169000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1042000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
412000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
337000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2450000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10812000 USD
bngo Proceeds From Payroll Protection Program Loan
ProceedsFromPayrollProtectionProgramLoan
1775000 USD
bngo Proceeds From Payroll Protection Program Loan
ProceedsFromPayrollProtectionProgramLoan
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
761000 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
3084000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2258000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2131000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16366000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2410000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
21000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
103000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18551000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30216000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11888000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8298000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17311000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16523000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18867000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8225000 USD
us-gaap Interest Paid Net
InterestPaidNet
991000 USD
us-gaap Interest Paid Net
InterestPaidNet
1036000 USD
us-gaap Stock Issued1
StockIssued1
4100000 USD
bngo Issue Common Stock For Covenant Waiver
IssueCommonStockForCovenantWaiver
300000 USD
bngo Deferred Equity Issuance Costs In Accounts Payable And Accrued Liabilities
DeferredEquityIssuanceCostsInAccountsPayableAndAccruedLiabilities
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000 USD
bngo Fair Value Of Warrants Issued With Debt Classified As Liability
FairValueOfWarrantsIssuedWithDebtClassifiedAsLiability
0 USD
bngo Fair Value Of Warrants Issued With Debt Classified As Liability
FairValueOfWarrantsIssuedWithDebtClassifiedAsLiability
630000 USD
bngo Transfer Of Instruments And Servers From Property And Equipment Into Inventory
TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
134000 USD
bngo Transfer Of Instruments And Servers From Property And Equipment Into Inventory
TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
360000 USD
bngo Transfer Of Instruments And Servers To Property And Equipment From Inventory
TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
2618000 USD
bngo Transfer Of Instruments And Servers To Property And Equipment From Inventory
TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
0 USD
bngo Issue Common Stock For Covenant Waiver
IssueCommonStockForCovenantWaiver
USD
bngo Fair Value Of Stock Issued With Debt Classified As Liability
FairValueOfStockIssuedWithDebtClassifiedAsLiability
0 USD
bngo Fair Value Of Stock Issued With Debt Classified As Liability
FairValueOfStockIssuedWithDebtClassifiedAsLiability
202000 USD
bngo Deferred Equity Issuance Costs In Accounts Payable And Accrued Liabilities
DeferredEquityIssuanceCostsInAccountsPayableAndAccruedLiabilities
197000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
35000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132000000.0 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18900000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35040000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6068000 shares
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2196000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3313000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4513000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7340000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2196000 USD
CY2019Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
39000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
299000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
117000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3313000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4513000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7340000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
500000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.276
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.612
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.076
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.036
CY2020Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
66000 USD
CY2020Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5749000 USD
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
6889000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1889000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
555000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3860000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6334000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1334000 USD
CY2020Q3 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
2622000 USD
CY2019Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
951000 USD
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1971000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2493000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
4593000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
3444000 USD
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
17635000 USD
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
21971000 USD
CY2020Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1621000 USD
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1886000 USD
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
16014000 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
20085000 USD
CY2020Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18000000.0 USD
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1600000 USD
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
24406000 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.76
CY2019 bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
P4Y9M25D
CY2019Q4 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
7933000 USD
bngo Class Of Warrant Or Right Number Of Securities Granted In Period
ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
95396000 shares
bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted In Period
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod
0.22
bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Granted In Period Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights
P4Y6M10D
bngo Class Of Warrant Or Right Number Of Securities Exercised In Period
ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
90093000 shares
bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised In Period
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod
0.21
bngo Class Of Warrant Or Right Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights
37150000 USD
bngo Class Of Warrant Or Right Number Of Securities Canceled In Period
ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod
0 shares
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
29709000 shares
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.54
bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
P4Y1M9D
CY2020Q3 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
1813000 USD
CY2020Q3 bngo Class Of Warrant Or Right Number Of Securities Vestedand Expectedto Vest Exercisable
ClassOfWarrantOrRightNumberOfSecuritiesVestedandExpectedtoVestExercisable
29709000 shares
CY2020Q3 bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Vestedand Expectedto Vest Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedandExpectedtoVestExercisable
1.54
bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Vestedand Expectedto Vest Exercisable Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermVestedandExpectedtoVestExercisableOfWarrantsOrRights
P4Y1M9D
CY2020Q3 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Vestedand Expectedto Vest Exercisable Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueVestedandExpectedtoVestExercisableOfWarrantsOrRights
0 USD
CY2020Q3 bngo Sale Of Stock Authorized Amount To Be Issued
SaleOfStockAuthorizedAmountToBeIssued
125000000.0 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1743000 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.73
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M15D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
353000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M21D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1119000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2659000 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
29800 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4250000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
662000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.52
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5331000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.55
CY2019Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4250000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
706640 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.67
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.82
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.35
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
447000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
364000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1103000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
990000 USD
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.779
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.682
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.748
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.682
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M6D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.07
CY2020Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.07
CY2019Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.45
CY2019Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.45
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.33
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.33
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-1.61
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-1.61

Files In Submission

Name View Source Status
0001411690-20-000022-index-headers.html Edgar Link pending
0001411690-20-000022-index.html Edgar Link pending
0001411690-20-000022.txt Edgar Link pending
0001411690-20-000022-xbrl.zip Edgar Link pending
bionano-ex104lineagent.htm Edgar Link pending
bionano-ex105lineagenm.htm Edgar Link pending
bionano-ex106employmen.htm Edgar Link pending
bionano-ex107employmen.htm Edgar Link pending
bngo-20200930.htm Edgar Link pending
bngo-20200930.xsd Edgar Link pending
bngo-20200930xexx311.htm Edgar Link pending
bngo-20200930xexx312.htm Edgar Link pending
bngo-20200930xexx321.htm Edgar Link pending
bngo-20200930_cal.xml Edgar Link unprocessable
bngo-20200930_def.xml Edgar Link unprocessable
bngo-20200930_htm.xml Edgar Link completed
bngo-20200930_lab.xml Edgar Link unprocessable
bngo-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending